R Squared Ltd Takes Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

R Squared Ltd acquired a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,450 shares of the biopharmaceutical company's stock, valued at approximately $205,000.

Other large investors have also recently modified their holdings of the company. True Wealth Design LLC bought a new position in Intra-Cellular Therapies in the third quarter valued at $32,000. GAMMA Investing LLC raised its holdings in Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 240 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of Intra-Cellular Therapies during the third quarter worth about $74,000. Wilmington Savings Fund Society FSB purchased a new stake in Intra-Cellular Therapies in the 3rd quarter worth approximately $97,000. Finally, Quarry LP boosted its holdings in Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after acquiring an additional 1,300 shares in the last quarter. Institutional investors own 92.33% of the company's stock.

Intra-Cellular Therapies Stock Up 0.1 %

NASDAQ ITCI traded up $0.07 on Wednesday, reaching $127.07. The company had a trading volume of 1,957,046 shares, compared to its average volume of 6,058,418. The stock has a market capitalization of $13.47 billion, a PE ratio of -146.08 and a beta of 0.70. Intra-Cellular Therapies, Inc. has a 12 month low of $62.78 and a 12 month high of $128.00. The firm's 50 day moving average price is $94.97 and its 200 day moving average price is $83.51.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $175.40 million during the quarter, compared to analysts' expectations of $172.30 million. During the same period last year, the business posted ($0.25) earnings per share. The company's revenue for the quarter was up 39.0% compared to the same quarter last year. On average, research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Insider Activity at Intra-Cellular Therapies

In related news, President Michael Halstead sold 22,869 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Sharon Mates sold 51,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the sale, the chief executive officer now directly owns 1,070,329 shares of the company's stock, valued at $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ITCI has been the topic of a number of research analyst reports. Piper Sandler reiterated a "neutral" rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. JPMorgan Chase & Co. lifted their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an "overweight" rating in a report on Monday, November 4th. Cantor Fitzgerald raised Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a report on Tuesday, January 14th. Morgan Stanley lifted their target price on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Finally, StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Thursday, January 23rd. They issued a "hold" rating on the stock. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $102.15.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.